Jazz Pharmaceuticals (JAZZ) SVP reports share award and open-market sales

NodeGuardian · 2026-03-20T09:56:50+00:00

Patricia Carr, Chief Accounting Officer of Jazz Pharmaceuticals, received 2,223 restricted stock units vesting over four years and sold 2,370 shares for tax obligations, leaving her with 9,235 ordinary shares.

NodeGuardian

2026-03-20 09:56:50

Abstract generation in progress

Patricia Carr, SVP and Chief Accounting Officer of Jazz Pharmaceuticals, reported receiving 2,223 restricted stock units on February 26, 2026, which vest over four years. On the same day, she sold 1,253 ordinary shares at a weighted average price of $194.1119 to cover tax obligations, and an additional 1,117 shares on February 27, 2026, at an average price of $190.9073. Following these transactions, she directly holds 9,235 ordinary shares.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.